vasopharm raises EUR 20M

vasopharm GmbH raised EUR 20 million ($21.8 million) in a venture round co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor Fort Rock Capital. Existing investors Bayern Kapital and funds advised by Hanseatic Asset Management also participated.

vasopharm plans to begin a Phase III study this half of VAS203, an allosteric nitric oxide (NO) synthase inhibitor to treat traumatic brain injury (TBI). The company's pipeline also includes VAS2870, a NADPH oxidase (NOX) modulator to treat peripheral arterial occlusive diseases. vasopharm did not respond to inquiries. ...